Recent News

Diagnosed with stage III breast cancer five months into pregnancy, Samar received specialized treatment at Burjeel Cancer Institute, safely delivered her baby, and completed chemotherapy and radiotherapy within a year. 

Abu Dhabi: When Samar began experiencing unusual breast pain during the fifth month of her pregnancy, she initially dismissed it as another change her body was undergoing in preparation for childbirth. She never imagined that the discomfort would lead to a diagnosis of stage III breast cancer. 

For the 40-year-old mother, the diagnosis brought an overwhelming fear. She was not only worried about surviving cancer but also about the safety of her unborn child. What followed was a challenging journey that saw her undergo chemotherapy during pregnancy, welcome her fourth child, and complete cancer treatment in less than a year. 

Samar’s symptoms first appeared in September 2025. “At first, I thought the pain and swelling were normal changes during pregnancy, as my body was preparing for breastfeeding. I never imagined that these symptoms could be signs of something as serious as breast cancer,” said Samar, a native of Jordan. However, persistent discomfort prompted her to consult Dr. Dima Abdul Jabbar, Consultant Medical Oncologist and Director of Burjeel Breast Center at Burjeel Cancer Institute in Burjeel Medical City. Further investigations confirmed stage III breast cancer, requiring immediate medical attention and a carefully coordinated treatment approach. 

At Burjeel Cancer Institute, a multidisciplinary team developed an individualized treatment plan considering the stage of her cancer, gestational age, and the health of her unborn baby. 

Samar began chemotherapy during her fifth month of pregnancy and continued treatment until two weeks before delivery. Following the safe birth of her son, Elias, she resumed chemotherapy just two weeks later. 

Treating Cancer While Protecting the Baby 

According to Dr. Dima, breast cancer diagnosed during pregnancy presents unique challenges, but treatment does not necessarily have to wait until childbirth. “Samar had been experiencing pain and swelling in her breast but thought that that these symptoms were normal and simply related to the changes in the mammary glands as the body prepares for childbirth and breastfeeding. However, these symptoms were actually warning signs of the disease,” said the doctor. “Fortunately, Samar decided to seek medical advice rather than ignore what she was feeling. Further investigations, including laboratory tests, medical imaging, and ultrasound examinations, confirmed the diagnosis.” 

Dr. Dima emphasizes that pregnancy-related breast changes can sometimes mask warning signs of cancer, making timely evaluation particularly important. The treatment required close coordination between medical oncologists, obstetricians, and gynecologists, with careful attention to both maternal health and fetal well-being. 

Samar was initially deeply anxious about chemotherapy thinking it would affect her baby. Counseling, medical guidance, and continuous reassurance helped her approach treatment with greater confidence. 

“What stood out most about Samar was the strength and composure she demonstrated as her treatment progressed. Her greatest motivation was the desire to recover, return to her children, and resume her normal life. She was an inspiring example of a mother who faced cancer with remarkable courage and remained committed to her treatment plan despite the many challenges she encountered,” she said, adding that certain chemotherapy regimens can be administered during specific stages of pregnancy, depending on various factors such as the type and stage of cancer and gestational age. 

The Birth of Elias: A Moment of Hope amid Cancer Treatment 

Amid the uncertainty of cancer treatment, the safe birth of Elias became a turning point in Samar’s journey. Her delivery was managed by the obstetrics and gynecology team at Burjeel Medical City in coordination with her oncology specialists. Holding her newborn son brought immense relief after months of worrying about his health. 

But her treatment journey was not yet complete. Samar subsequently underwent a complete mastectomy of her right breast and completed her prescribed chemotherapy and radiotherapy. She is now looking forward to breast reconstruction surgery as the next stage of her recovery. 

Her Husband Shaved His Head in Solidarity 

Throughout the experience, her family remained an important source of strength. One gesture from her husband remains particularly meaningful. 

My husband was my greatest source of strength during the most difficult moments of my treatment. When I started losing my hair because of chemotherapy, he shaved his head to show his support. It was a simple gesture, but it meant so much to me. It reminded me that I was not facing this battle alone,” Samar recalled. “I am also thankful to the medical and nursing teams at Burjeel Cancer Institute, especially Dr. Dima, for supporting me emotionally throughout treatment. 

Today, Samar is back with her family and four children, including Elias, having completed chemotherapy and radiotherapy within a year of her diagnosis. Her story has an important message for expectant mothers. Persistent breast pain, swelling, or unusual changes should never be dismissed as normal pregnancy symptoms without medical evaluation.

The injection was given to a 43-year-old Emirati male patient who had been living with the condition for more than five years, experiencing symptoms including nose block, loss of smell, and recurrent sinus infections 

Abu Dhabi: Burjeel Medical City (BMC), the flagship facility of Burjeel Holdings, has administered Exdensur (depemokimab), an ultra-long-acting biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), for the first time in the Gulf region, with the support and oversight of the Department of Health – Abu Dhabi (DoH). 

The treatment represents a new option for patients whose symptoms continue to recur despite conventional medical treatment and surgery. Given as an injection under the skin, depemokimab is designed to provide sustained control of the underlying sinus inflammation over a six-month dosing interval.  

The injection was given to a 43-year-old Emirati male patient who had been living with the condition for more than five years, experiencing symptoms including nose block, loss of smell, and recurrent sinus infections. The patient had previously undergone two sinus surgeries, but the relief was temporary, and his symptoms eventually returned.  

The therapy was administered by the ENT team led by Dr. Yogesh More, Consultant & Co-Director of the Burjeel ENT Head & Neck Institute. 

“Most people experience nose-sinus issues at some point in their lives. However, when symptoms persist over a prolonged period and are associated with polyps, they can significantly affect quality of life. In this particular case, the symptoms affected his sense of smell, preventing him from enjoying food aromas and perfumes. Frequent nasal blockage caused disturbed, unrefreshing sleep leading to daytime sleepiness and fatigue. Overall, it affected his energy levels, resulting in a poor quality of life. The sinus allergies flared up during local seasonal changes in the UAE as well as after travel,” said Dr. More. 

The patient showed improvement in his nasal and sinus symptoms after receiving the treatment and regained his sense of smell.  “One of the most important benefits we have seen is the return of the patient’s sense of smell. Existing treatment options, including sinus surgery and steroids, do not always provide sufficient improvement in this area. When used alongside sinus surgery, this treatment can also help reduce the recurrence of nasal polyps,” added Dr. More. 

Depemokimab is a long-acting biologic treatment that targets one of the key drivers of the inflammation behind the disease. It can be administered to eligible adult patients with sinusitis and nasal polyps who have high type 2 inflammation and have failed adequate medical and surgical management, with the disease significantly affecting their daily lives. A single dose is designed to keep this inflammation under control for up to six months, helping reduce the activity of the immune cells that contribute to recurring symptoms. 

“Chronic sinusitis is commonly managed using treatments such as antihistamines, nasal sprays, while surgery is reserved for advanced cases. Some patients continue to experience recurrent disease despite these interventions. For them, biologic therapies, provide an attractive alternative,” said Dr. More. “Extending the interval between doses to once every six months may be particularly valuable for eligible patients, helping them balance their treatment needs with their personal and professional commitments, while supporting disease control and improving their quality of life,” explained the doctor. 

He emphasized that, for patients selected according to appropriate clinical criteria, biologic treatment can also help reduce the risk of disease recurrence and the need for additional surgery. He also stressed the importance of patients experiencing persistent or recurrent symptoms consulting a specialist for a thorough medical evaluation and accurate diagnosis to determine the most appropriate treatment plan based on each patient’s condition. 

The milestone reinforces Burjeel Medical City’s focus on bringing advanced, evidence-based therapies closer to patients with complex and long-standing ENT conditions. 

Three of the nine recognized institutions in Abu Dhabi are part of Burjeel Holdings, highlighting the Group’s strength in specialized healthcare and medical tourism 

Abu Dhabi, November 4, 2026: Four hospitals of Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC, have been recognized in Newsweek’s World’s Best Hospitals & Clinics for Medical Tourism 2027, reinforcing the Group’s position as a provider of specialized healthcare and its growing contribution to the UAE’s medical tourism sector. 

The recognition spans three key specialties: Orthopedics, Ophthalmology, and Cardiac Care. Of the nine institutions recognized in the emirate of Abu Dhabi, three are Burjeel Holdings hospitals, accounting for one-third of the recognized facilities. A fourth hospital in Sharjah has also been included, reflecting the strength of specialized care across the Group’s network. 

Burjeel Medical City, the flagship facility of Burjeel Holdings, has been recognized for Orthopedics, while Burjeel Hospital, Abu Dhabi, has earned recognition for Ophthalmology. Burjeel Royal Hospital in Al Ain has been recognized for Cardiac Care, and Burjeel Specialty Hospital in Sharjah has been recognized in two specialties: Cardiac Care and Orthopedics. 

The recognition is part of Newsweek’s World’s Best Hospitals & Clinics for Medical Tourism, developed in partnership with global data and business intelligence platform Statista. The assessment evaluated more than 25,000 hospitals worldwide and recognized 295 hospitals and clinics across 13 countries. 

The rankings assess healthcare facilities serving international patients based on multiple criteria, including recommendations from medical professionals and medical tourism facilitators, accreditations and certifications, patient experience, and international patient services. The evaluation also incorporates findings from the Statista Medical Tourism Facility Survey. 

Commenting on the recognition, Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, said, “This recognition reflects the visionary leadership of the UAE, which has made healthcare excellence and innovation a national priority. We are deeply grateful to the leadership of the Department of Health – Abu Dhabi for its continued guidance, encouragement, and support in raising healthcare standards. Above all, this achievement belongs to our doctors, nurses, and every member of the Burjeel family. Their dedication and commitment make milestones like this possible. This is a proud moment for all of us and a reminder of our shared responsibility to continue advancing the UAE’s position as a global healthcare destination.” 

Advancing Specialized Care Through Burjeel 2.0 

The recognition comes as Burjeel Holdings advances its Burjeel 2.0 transformation strategy, focused on strengthening clinical capabilities, expanding complex and specialized medicine, enhancing patient experience, and building a more connected healthcare network. 

Under this strategy, the Group is strengthening its high-acuity and specialized care capabilities through investments in advanced medical technologies, multidisciplinary expertise, and integrated clinical pathways.  

At its flagship facility, BMC, the Group continues to advance complex medicine through specialized clinical programs, including the Burjeel Orthopedic Institute and Paley Middle East Clinic, which attract international patients from across the world for advanced orthopedic treatments, including limb reconstruction, deformity correction, and complex orthopedic surgery. BMC’s orthopedic services have also received specialized center accreditation from the Department of Health – Abu Dhabi. 

The recognition further supports the Group’s ambition to attract more international patients to the UAE, reinforcing its commitment to developing advanced clinical capabilities and strengthening the country’s position as a global healthcare destination. 

Signed at the Abu Dhabi Future Health Summit 2026, the collaboration brings together healthcare AI and surgical intelligence expertise to position Burjeel as a regional reference for AI-enabled operating rooms. 

Abu Dhabi, October 22, 2026: AiMed Solutions, an intelligent healthcare development and operating platform of Burjeel Holdings, has partnered with Proximie, the global surgical intelligence platform for the operating room (OR), to jointly develop advanced AI-powered solutions for surgical care. To formalize the partnership, a Memorandum of Understanding (MoU) was signed at the Abu Dhabi Future Health Summit 2026, establishing a four-stage co-development program that builds on the ongoing implementation of the surgical intelligence platform at Burjeel Medical City in Abu Dhabi. 

The MoU was signed by Safeer Ahamed, Group Head of Shared Services at Burjeel Holdings, and Dr. Nadine Hachach-Haram, Founder and CEO of Proximie. 

The collaboration will combine AiMed Solutions’ expertise in healthcare system development, clinical workflow transformation, and AI integration with Proximie’s surgical intelligence technology and engineering capabilities. Drawing on experience from the deployment of over two dozen AI applications across clinical care and operations within the wider healthcare ecosystem, AiMed Solutions will work alongside Proximie and Burjeel’s clinical teams to co-develop intelligent solutions that improve operating room efficiency, strengthen clinical decision-making, and enable more connected surgical workflows. 

Safeer Ahmed, Group Head of Shared Services at Burjeel Holdings, said, “The real value of AI in healthcare lies in shaping technology around the needs of clinicians and patients. The operating room is a highly complex environment where precision, coordination, and timely decisions are critical. By bringing clinical expertise directly into the development process, we want to create intelligent solutions that are practical, scalable, and capable of setting new standards for surgical care. This is how we see the future of healthcare innovation, where technology is developed with clinicians, not just for them.” 

Dr. Nadine Hachach-Haram, Founder and CEO of Proximie, said, “The best surgical care depends on every team knowing what is happening in the operating room and what needs to happen next. Proximie’s surgical intelligence platform gives them that, predicting how the day will run and recommending the right next step. Burjeel has a clear view of the intelligent operating room it wants to build, and it has been a real pleasure working with a team whose ambition matches our own. The future of surgery will be shaped by innovative partnerships like this, so every patient has a smoother, more predictable surgical journey.” 

Co-Developing the Next Generation of Intelligent Operating Rooms 

The ongoing implementation of Proximie’s surgical intelligence platform at Burjeel Medical City covers computer vision, electronic medical record connectivity, real-time surgical intelligence, and multi-site functionality across 10 operating rooms. This forms the foundation for Burjeel’s ONE OR initiative, encompassing 45 functional requirements to be advanced through a four-stage co-development roadmap. 

The first stage will put real-time surgical intelligence in the hands of everyone running the surgical day. On shared screens and their phones, teams will see how each room is performing and where time is being gained or lost, get alerts when the next step is due, and AI-supported clinical documentation. The second stage will improve productivity through agentic AI, workflow monitoring, surgical safety checklists, and bed management. 

The third stage will extend surgical intelligence to endoscopy, cardiac catheterization laboratories, and interventional radiology, while improving patient journey coordination and family communication. The fourth stage will focus on surgical instrument tracking and advanced clinical, operational, and financial performance indicators. 

Deployed in more than 700 operating rooms, Proximie’s AI-powered platform combines real-time surgical data from ambient sensors, medical devices, and electronic medical records, giving teams the full picture of the operating room as the day unfolds., It’s AI models understand what is happening in each room, anticipate potential delays, and recommend next steps throughout the perioperative journey. The co-development program will build on these capabilities to develop additional AI-powered solutions tailored to clinical and operational requirements. 

Over the years, Burjeel Holdings has strengthened its complex surgical capabilities across multiple specialties, including robotic and minimally invasive surgery, advanced orthopedic procedures, cardiovascular interventions, surgical oncology, fetal surgery, and multiorgan transplantation. The initiative also aligns with the Group’s Burjeel 2.0 transformation strategy, which prioritizes faster decisions, clinical excellence, and integrated operations.

Signed on the sidelines of the Abu Dhabi Future Health Summit 2026, the collaboration will explore joint research, AI and digital health innovation, specialized education, and opportunities to develop the UAE’s next generation of healthcare and research talent 

Abu Dhabi, October 22, 2026: Burjeel Training Academy, the education and professional training arm of Burjeel Holdings, has signed a Memorandum of Understanding (MoU) with New York University Abu Dhabi (NYUAD) to strengthen collaboration in healthcare research, medical innovation, professional education, and talent development. 

Signed on the sidelines of the Abu Dhabi Future Health Summit 2026 at ADNEC Centre Abu Dhabi, the agreement establishes a three-year framework that brings together NYUAD’s academic and research expertise with Burjeel’s clinical capabilities and healthcare network. The collaboration aims to create opportunities for interdisciplinary research, accelerate the translation of scientific innovations into clinical practice, and develop specialized skills to support the evolving needs of the healthcare sector. 

Dr. Tahani Al Qadiri, Associate Vice President, Burjeel Training Academy, and Marta Losada, Interim Provost of NYU Abu Dhabi signed the MoU in the presence of Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings. 

Bridging Academic Research and Clinical Practice 

A central focus of the collaboration will be joint research bringing NYUAD faculty and researchers together with Burjeel clinicians. Potential areas include artificial intelligence (AI) in healthcare, precision medicine, oncology, genomics, mental health, rehabilitation, population health, and healthcare workforce research. 

The institutions will also explore opportunities to pilot and clinically validate promising research innovations within Burjeel facilities, particularly in medical devices, diagnostics, cancer care, rehabilitation technologies, and digital health. This includes developing and testing AI-enabled solutions for clinical decision support, predictive analytics, personalized medicine, workflow optimization, and patient experience. 

“The future of healthcare depends on how effectively we connect academic research, professional education, and clinical practice. Through this collaboration with NYU Abu Dhabi, we aim to create meaningful opportunities for our healthcare professionals to engage in advanced research, develop expertise in emerging technologies, and translate innovative ideas into practical solutions. Equally important is our focus on nurturing Emirati research talent and building the capabilities that will shape the next generation of healthcare in the UAE,” said Dr. Tahani Al Qadiri. 

Beyond research, the MoU identifies opportunities for capacity building and professional development. These include customized executive education programs covering healthcare leadership, AI, data science, digital transformation, innovation, and change management. The institutions will also explore pathways for selected Burjeel employees to pursue NYUAD’s MSc in Interdisciplinary Data Science and Artificial Intelligence (MIDSAI). 

Marta Losada, Interim Provost of NYU Abu Dhabi, said: “Collaborations between universities and healthcare institutions, such as our partnership with Burjeel Training Academy, create valuable opportunities to bring different areas of expertise together and address some of the most pressing challenges in healthcare. By combining NYU Abu Dhabi’s strengths in interdisciplinary research, AI, data science, and life sciences with Burjeel’s clinical expertise, we can create new opportunities for research and learning, while helping prepare the next generation of researchers and healthcare professionals in the UAE.”     

Developing national research capabilities is another priority. The collaboration will explore establishing a Burjeel-supported track under NYUAD’s Kawader Research Assistantship Program, focused on healthcare and life sciences, to help young Emirati researchers build expertise and contribute to the UAE’s research and development ecosystem. 

Additional areas include structured research opportunities for Burjeel physicians, residents, fellows, nurses, and other healthcare professionals through participation in NYUAD research projects, laboratories, mentorship, and research methodology training. The institutions will also explore academic and research collaboration across postgraduate medical education programs. 

The agreement further outlines opportunities for student engagement, including internships, project-based learning, career exposure, and potential scholarship support for outstanding NYUAD students pursuing disciplines relevant to healthcare, science, technology, and AI. 

The collaboration also envisions joint healthcare innovation challenges and hackathons bringing together students, researchers, and clinicians to address practical healthcare challenges and explore opportunities to advance promising solutions toward clinical pilots. 

Through scientific conferences, research seminars, visiting faculty initiatives, and other knowledge-exchange activities, the collaboration seeks to strengthen connections between academia and healthcare delivery while supporting the UAE’s ambitions in research, innovation, and developing a highly skilled healthcare workforce. 

Signed at the Abu Dhabi Future Health Summit 2026, the agreement will evaluate AI-assisted ECG interpretation, building on Burjeel’s advanced cardiac care capabilities and its Burjeel 2.0 transformation strategy 

Abu Dhabi, October 21, 2026: Burjeel Hospital Abu Dhabi has signed a Memorandum of Understanding (MoU) with South Korea-based ARPI Inc. to explore the clinical validation of AI-powered electrocardiogram (ECG) interpretation technology. The collaboration aims to strengthen early identification of cardiovascular disease and support timely, informed clinical decisions. 

The MoU was signed at the Abu Dhabi Future Health Summit in the presence of H.E. Lee Won-ik, Ambassador of the Republic of Korea to the UAE, and Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings. Dr. Ashiq Moideen of Burjeel Hospital and Joonghee Kim, CEO of ARPI Inc., signed the MoU. 

The collaboration supports Burjeel 2.0, the Group’s transformation strategy focused on strengthening clinical excellence, accelerating decision-making, and expanding complex care capabilities through advanced technologies. It brings together Burjeel’s cardiovascular expertise and ARPI’s diagnostic technology to explore new approaches to early detection and clinical assessment. 

Bringing Korean AI Innovation to UAE Clinical Practice   

At the center of the collaboration is ECG Buddy, ARPI’s AI-powered ECG interpretation and clinical decision-support solution. Designed to help healthcare professionals analyze electrocardiograms, the technology can identify cardiac rhythm abnormalities and provide additional insights into potential cardiovascular risks. The partnership will explore pilot implementation and clinical validation within Burjeel’s healthcare facilities to assess its performance and potential clinical benefits. 

The initiative builds on Burjeel Hospital’s growing capabilities in advanced cardiovascular medicine. The hospital recently introduced one of the GCC’s first-of-its-kind AI-powered catheterization laboratories, equipped with Siemens Healthineers’ ARTIS icono.vision platform. Combining AI-assisted imaging, advanced 3D visualization, and real-time procedural guidance, the facility supports complex interventional cardiology, structural heart procedures, and other minimally invasive treatments. 

Together with its specialist cardiac services and multidisciplinary clinical teams, these capabilities support a coordinated approach to cardiovascular care, from initial assessment and diagnosis to advanced interventions. 

Dr. Georgie Thomas, Consultant Interventional Cardiologist & HOD, Burjeel Hospital Abu Dhabi, said, “In cardiac care, the decisions made during the initial assessment can shape the entire patient journey. AI can help physicians recognize key diagnostic signals earlier and make more informed decisions. But for any technology to deliver meaningful clinical value, it must be rigorously evaluated and integrated responsibly into existing care pathways. Through this collaboration, we want to ensure that innovation translates into earlier detection, timely interventions, and better outcomes for our patients.” 

Under the agreement, the two organizations will explore retrospective and prospective clinical validation studies using anonymized ECG data. These studies may assess diagnostic accuracy, sensitivity, specificity, workflow efficiency, and clinical utility to determine how the technology performs within local healthcare settings. The collaboration also provides opportunities for joint clinical research, scientific publications, and knowledge exchange between healthcare and technology experts in the UAE and South Korea. 

Dr. Jisoon Park, Director of the Korean Pavilion at Burjeel Hospital Abu Dhabi, said, “South Korea has made significant advances in medical technology and clinical innovation, and this partnership offers an opportunity to bring that expertise to the UAE. Building on the strong connections between our healthcare systems, the collaboration will explore how Korean-developed AI technologies can support clinical practice, strengthen knowledge exchange, and improve patient care in the region.” 

According to ARPI, ECG Buddy has received regulatory approval from South Korea’s Ministry of Food and Drug Safety (MFDS) and holds CE certification. The company reports that its technology is used in more than 150 hospitals in South Korea and processes approximately 300,000 ECGs each month. 

Joonghee Kim, CEO of ARPI Inc., said: “Our partnership with Burjeel Hospital represents an important opportunity to bring AI-powered ECG interpretation into a new clinical environment and evaluate its potential to support cardiovascular care. By combining ARPI’s technological expertise with Burjeel’s advanced clinical capabilities, we aim to generate meaningful clinical evidence and explore how AI can help healthcare professionals identify cardiovascular risks and make more informed decisions. We look forward to advancing this collaboration and contributing to the development of AI-enabled cardiac diagnostics in the region.” 

A joint working group comprising clinical, research, regulatory, IT, and business representatives will coordinate the proposed studies, review clinical workflow and regulatory requirements, and assess next steps. Subject to successful clinical validation, applicable regulatory approvals, and mutually agreed terms, the organizations may explore wider implementation across Burjeel facilities and potential opportunities in the GCC and the broader Middle East and North Africa region. The collaboration reinforces Burjeel Holdings’ commitment to evidence-based innovation under Burjeel 2.0, combining advanced clinical capabilities with emerging technologies to improve the quality, efficiency, and accessibility of specialized cardiovascular care. 

• Signed at the Abu Dhabi Future Health Summit, the UK–UAE collaboration aims to connect patient-derived cancer research, AI-driven innovation, and clinical development to accelerate new therapies. 

• Avatrial, co-founded by Cambridge University Hospitals NHS Foundation Trust and Prof. Kourosh Saeb-Parsy, brings advanced British biotechnology expertise to the proposed collaboration. 

Abu Dhabi, 20 October 2026: Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC, has signed a Memorandum of Understanding (MoU) with Avatrial, a UK-based biotechnology company co-founded by Cambridge University Hospitals NHS Foundation Trust and Prof. Kourosh Saeb-Parsy, to explore the development of a first-of-its-kind integrated AI-powered cancer drug discovery ecosystem in Abu Dhabi. 

The MoU was signed at the Abu Dhabi Future Health Summit in the presence of Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings. Prof. Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, and Prof. Kourosh Saeb-Parsy, Founder and CEO of Avatrial and Professor at the University of Cambridge, signed the agreement. 

The collaboration will bring together Burjeel Holdings’ clinical expertise and patient-centered research infrastructure with Avatrial’s AI-powered biotechnology platform. The proposed model aims to use insights from cancer patients to identify and develop promising new treatments, with the potential to advance them into clinical trials. 

The initiative supports Burjeel 2.0, the Group’s transformation strategy to advance complex care, clinical research, and AI integration across its healthcare ecosystem. It also reflects Burjeel’s broader ambition to build capabilities in therapeutic innovation while contributing to support Abu Dhabi’s vision of becoming a global hub for life sciences, precision medicine, and healthcare innovation. 

From Patient to Therapy and Back 

The proposed discovery-to-clinic model will integrate clinical data, molecular analysis, and experimental research to investigate the biological mechanisms of cancer and identify potential treatment approaches. It will leverage Burjeel Holdings’ clinical network and Burjeel Cancer Institute's oncology expertise, alongside Avatrial’s multi-omics technologies and patient-derived experimental models. 

Through this framework, ethically consented surplus tumor tissue and de-identified clinical data could be analyzed, subject to the necessary regulatory and ethical approvals. AI-assisted molecular profiling would help researchers identify potential therapeutic targets, while patient-derived models would be used to assess and validate promising drug candidates. 

Candidates that demonstrate potential through preclinical evaluation could subsequently enter clinical development, subject to further agreements and regulatory approvals. Nurion CRO, affiliated with Burjeel, is expected to support the clinical research and trial development process. 

Prof. Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, said, “Our ambition is to move beyond conducting clinical trials of medicines developed elsewhere and become an active contributor to the discovery and development of new therapies. By connecting our patients, clinical expertise, and research infrastructure with Avatrial's advanced discovery platform and the University of Cambridge’s preclinical research capabilities, we aim to build an ecosystem where scientific discoveries originate from real-world patient needs and ultimately translate into new treatment opportunities. This collaboration reflects our commitment to positioning Abu Dhabi as a global destination for biotechnology innovation and drug development.” 

Prof. Kourosh Saeb-Parsy, Founder and CEO of Avatrial, said, “Our mission is to eliminate waste and noise from every step of preclinical cancer drug discovery to help develop better therapies faster. We do this by connecting patient tissue, deep multi-omic data, AI-driven analysis, and patient-derived models in one continuous re-iterating loop. Burjeel's clinical network and ambition help us create important synergies in Abu Dhabi, and we see the potential for this model to serve patients across the GCC and beyond. We are delighted to be partnering with Burjeel.” 

Building on Burjeel’s Cancer Care and Research Capabilities 

Burjeel brings an established foundation in complex oncology, precision medicine, and translational research to the proposed partnership. Through BCI, the Group has developed a multidisciplinary oncology ecosystem, supported by advanced diagnostic imaging, molecular profiling, and specialized treatments spanning medical, surgical, and radiation oncology. Burjeel Medical City in Abu Dhabi serves as a flagship center for complex cancer care, bringing together multidisciplinary teams to manage challenging cases. 

BCI has expanded its regional reach with specialty centers and international collaborations, supporting access to advanced treatment options, specialist expertise, and multidisciplinary care. 

The Group’s research portfolio includes clinical trials, scientific collaborations, and programs focused on rare blood disorders, precision medicine, and emerging cell and gene therapies. Its Center for Research on Rare Blood Disorders (CR-RBD) has established a strong international research presence, contributing to advances in diagnosing and treating complex hematological conditions. 

Together, these clinical and research capabilities provide a foundation for investigating potential therapies and evaluating their relevance to patients across the region. 

The collaboration also creates opportunities for closer scientific cooperation between the UAE and the United Kingdom, combining regional clinical expertise with international biotechnology research capabilities. 

A Phased Approach to Innovation 

The collaboration will begin with a feasibility program involving selected solid tumors to assess integrating clinical samples, molecular profiling, AI-based analysis, and experimental validation within a coordinated research framework. 

The findings will inform decisions on potential joint therapeutic development programs, opportunities to strengthen local research infrastructure, and the expansion of scientific capabilities in Abu Dhabi. Over time, the model could extend beyond oncology into other therapeutic areas, including rare and inherited diseases.

Abu Dhabi, 16 October 2026: Burjeel Cancer Institute has introduced therapeutic radiopharmaceuticals treatment for patients with certain types of tumours, as part of the institute’s ongoing efforts to provide the latest evidence-based cancer therapies in line with international standards, supporting Abu Dhabi’s position as a leading destination for advanced healthcare. 

The treatment works by precisely targeting tumour cells through specific receptors expressed on their surface, allowing radioactive therapies to be delivered directly to the tumours while minimising exposure to surrounding healthy tissues.  

The availability of this treatment is supported by the Department of Health – Abu Dhabi (DoH), as part of its unwavering commitment to expediting access to high-impact innovative treatments that improve health outcomes, and marks an important advancement in cancer care through the expansion and use of therapeutic radiopharmaceuticals, which allows personalised treatment plans based on the biological characteristics of each tumour. 

The therapy is delivered at the Nuclear Medicine Department at Burjeel Medical City, Abu Dhabi, which is equipped with state-of-the-art technology and supported by a highly specialised multidisciplinary team that includes nuclear medicine physicians, medical oncologists, medical physicists, nuclear medicine technologists, and radiation safety experts, ensuring the highest standards of quality and patient safety. 

Prof Humaid Al Shamsi, CEO of Burjeel Cancer Institute, said: “The introduction of therapeutic radiopharmaceuticals represents an important milestone in the institute’s strategy to expand advanced cancer care services. The institute continues to invest in innovative technologies and highly specialised treatments in alignment with the UAE’s vision to enhance healthcare quality and provide patients with access to the most advanced therapies within the country”.  

He added: “Offering such cutting-edge treatments reflects the institute’s commitment to building a comprehensive oncology care model based on innovation, multidisciplinary collaboration, and improved patient outcomes”. 

Dr Ibrahim Abu Gheida, Medical Director of Burjeel Cancer Institute, said: “The introduction of the treatment further strengthens the institute’s capabilities in nuclear medicine and targeted molecular oncology. This type of therapy requires advanced infrastructure and a highly experienced specialised team to ensure optimal clinical outcomes while maintaining the highest safety standards, adding that the institute continues to develop advanced treatment programmes based on the latest scientific evidence in cancer care”. 

Dr Firuz Ibrahim, Head of Nuclear Medicine at Burjeel Medical City, said: “The availability of this advanced therapy at Burjeel Cancer Institute allows patients to receive world-class treatment within the UAE. The goal is to provide comprehensive, patient-centred care supported by the latest global medical technologies”. 

Dr Goncalo Ferreira, Consultant in Nuclear Medicine at Burjeel Medical City, said: “The introduction of the treatment marks a significant step forward in the development of nuclear medicine services, reflecting the advanced expertise of the clinical team in delivering highly precise molecular therapies in accordance with international standards”. 

The launch of this advanced therapy reflects Burjeel Cancer Institute’s commitment to supporting the UAE’s national healthcare priorities and strengthening its role as a regional centre of excellence in advanced, specialised medical care capable of managing complex oncological cases according to the highest international standards.

The Institute being developed by Burjeel Holdings will strengthen advanced care for blood disorders, stem cell transplantation, and emerging cell and gene therapies. 

Abu Dhabi, 14 October 2026: Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC, is developing an international Hematology Institute in the UAE under the leadership of Prof. Alok Srivastava, a global pioneer in hematology and stem cell transplantation whose work has helped shape international treatment standards and advance gene therapy research. With Burjeel Medical City in Abu Dhabi as its flagship hub, the Institute aims to become a leading destination for complex blood disorders, stem cell transplantation, and advanced therapies, bringing together specialized patient care, scientific research, and medical education. 

Prof. Srivastava, who has been named Chairman of the Group-Wide Hematology Institute, will spearhead the initiative under Burjeel 2.0, the Group’s transformation strategy focused on developing advanced clinical capabilities and globally competitive specialty centers. The Institute will bring together existing clinical expertise and research capabilities while strengthening specialist referrals, multidisciplinary treatment, and access to advanced care. 

Known internationally for shaping hemophilia treatment guidelines and advancing gene therapy research, Prof. Srivastava brings more than three decades of experience in adult and pediatric hematology, stem cell transplantation, and academic leadership. He will spearhead the development of an integrated clinical and academic platform spanning hematology, hemato-oncology, bone marrow transplantation, and emerging cell and gene therapies. 

A Global Leader in Hematology and Scientific Innovation 

Prof. Srivastava spent more than 35 years at Christian Medical College (CMC), Vellore, India, where he helped develop one of the country’s leading bone marrow transplantation programs. He also established and led the Centre for Stem Cell Research, a unit of India’s Institute for Stem Cell Science and Regenerative Medicine (inStem), advancing stem cell research and gene therapy technologies. 

A globally recognized authority on hemophilia, he led the development of all three editions of the World Federation of Hemophilia’s (WFH) Guidelines for the Management of Hemophilia, helping shape clinical practice worldwide. He currently serves on the WFH Board of Directors, having previously served as Vice-President (Medical) from 2012 to 2014. He is Chairman of the Association for Haemophilia and Allied Disorders – Asia Pacific. His contributions have earned him the International Society on Thrombosis and Haemostasis (ISTH) Esteemed Career Award in 2024. He is also President of the Asia-Pacific Blood and Marrow Transplantation Group. 

Prof Srivastava’s pioneering research includes a first-in-human clinical study of lentiviral vector-based gene therapy for severe hemophilia A, published in the New England Journal of Medicine in 2025. This study demonstrated a novel approach for gene therapy for hemophilia with sustained production of clotting factor VIII using genetically modified blood-forming stem cells. The findings represent an important advance toward potentially curative treatments. 

Prof. Srivastava has authored hundreds of peer-reviewed scientific publications and continues his academic research at St. John’s Research Institute and St. John’s Medical College Hospital in Bengaluru, India. 

“Burjeel has made a clear commitment to building a hematology and transplantation service that can stand alongside the best centers in the world. Many families in this region live with inherited blood disorders such as thalassemia and sickle cell disease, and too many still have to travel abroad for transplants and advanced therapies. We aim to offer these treatments here in the UAE in a patient centered approach, supported by strong clinical programs, research, and the training of the next generation of specialists. I am delighted to lead this work,” said Prof. Srivastava. 

Building on Established Clinical Capabilities 

The Institute will build on Burjeel Holdings’ expertise in complex, highly specialized care. Burjeel Cancer Institute at BMC provides comprehensive adult and pediatric hematology and hemato-oncology services, including treatment for leukemia, lymphoma, multiple myeloma, bone marrow failure, and inherited blood disorders. 

Its bone marrow transplantation program offers autologous and allogeneic stem cell transplantation for eligible patients, supported by specialized teams and multidisciplinary care. BMC’s Thalassemia and Sickle Cell Center provides specialist consultations, transfusions, disease-modifying treatments, and transplantation expertise, while the Center for Research on Rare Blood Disorders (CR-RBD) has become one of the most productive research hubs worldwide. 

Under Prof. Srivastava’s leadership, these capabilities will form the foundation for internationally benchmarked clinical programs, expanded transplantation services, and research-driven advanced treatments. Strengthening these services locally will also help address the needs of patients, while reducing reliance on overseas treatment. 

Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, said: “The future of healthcare leadership will not be defined by the number of hospitals we operate, but by the scientific institutions we build and the medical advances we bring to patients. Professor Alok Srivastava represents the kind of global scientific leadership around which we intend to build Burjeel’s next generation of institutions. Our ambition is to establish Abu Dhabi as an internationally recognized destination for complex blood disorders, stem cell transplantation, and emerging cell and gene therapies. We want to move beyond delivering advanced treatment to contributing to the science, research, training, and clinical standards that shape healthcare globally.” 

Advancing Research and the Next Generation of Specialists 

The Institute will expand care for the full spectrum of pediatric and adult hematological disorders, both benign and malignant, while exploring opportunities in cellular and gene-based therapies through local innovation, research collaborations and international partnerships. 

A key priority will be building a strong academic foundation through clinical research, specialist training, and knowledge exchange, supporting the development of the next generation of hematologists, transplant specialists, and multidisciplinary healthcare professionals.

International recognition highlights Burjeel’s growing contribution to scientific research across oncology, hematology, genetics, and surgery 

Abu Dhabi, 10 October 2026: Four expert physicians from Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC, have been included in the World’s Top 2% Most Cited Scientists database for 2026, recognizing the international impact of their research across oncology, hematology, medical genetics, and surgery. Developed by researchers associated with Stanford University using Elsevier’s Scopus citation data, the database identifies scientists with significant research citation impact across scientific disciplines.  

Prof. Humaid O. Al-Shamsi, Prof. Khaled M. Musallam, Prof. Ayman W. El-Hattab, and Prof. Basil J. Ammori feature in the latest edition, reflecting the depth of scientific expertise across Burjeel’s clinical teams and the contribution of UAE-based physicians to global medical research. 

Their inclusion reinforces Burjeel’s commitment to integrating clinical excellence with scientific research and academic collaboration, supporting the advancement of medical knowledge and its application in patient care.  

Research contributions across four specialties 

Prof. Humaid O. Al-Shamsi, CEO of Burjeel Cancer Institute and President of the Emirates Oncology Society, is recognized in the Oncology & Carcinogenesis subfield. Prof. Al-Shamsi ranked within the top 1.2% of researchers worldwide in his specialty based on citation impact during 2025. His research contributions span cancer care, precision oncology, and clinical studies, supporting efforts to advance cancer treatment across the region.  

 Prof. Khaled M. Musallam, Group Chief Research Officer at Burjeel Holdings and Deputy CEO and Chief of Hematology and Cell & Gene Therapy at Burjeel Cancer Institute, appears in both the single-year and career-long citation-impact databases. His research in hematology, particularly thalassemia, has contributed to advances in patient management and the development of novel therapies over the past two decades.  

 Prof. Ayman W. El-Hattab, Director of the Genetics and Rare Disease Center, is recognized in Genetics & Heredity and appears in both the single-year and career-long databases. His research focuses on medical genetics, rare genetic disorders, and inherited diseases, contributing to the understanding of complex conditions and approaches to their diagnosis and management.  

 Prof. Basil J. Ammori, Consultant Laparoscopic, Bariatric, General, Gastrointestinal and Hepatobiliary Surgeon at Burjeel Hospital Abu Dhabi, is recognized in Surgery. Included in both the single-year and career-long databases, his research has contributed to surgical practice, particularly in minimally invasive and gastrointestinal surgery. 

Supporting physician-led research 

The 2026 database incorporates citation data through the end of 2025 and provides separate assessments of career-long and single-year research impact. Its methodology considers citation counts, h-index, co-authorship-adjusted measures, and a composite citation score that accounts for authorship position. 

Researchers are included based on their composite citation-impact ranking or their position among the top 2% within their scientific subfield. 

For Burjeel, the recognition highlights the importance of supporting physicians who contribute to scientific knowledge alongside their clinical responsibilities. The Group continues to promote physician-led research and international academic collaboration, with a focus on translating advances in medical knowledge into improvements in patient care.  

• Dedicated platform brings together brands contributing more than 20% of Group revenue, with Dr. Narendra D Sonigra appointed as CEO. 

• Supported by more than 2,400 healthcare professionals, the platform recorded over 2.3 million outpatient visits and more than 61,000 admissions. 

Abu Dhabi, 12 October 2026: Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC, has established a dedicated affordable healthcare vertical, bringing together its LLH, Lifecare, and Medeor brands under a unified leadership structure. 

Dr. Narendra D Sonigra has been appointed Chief Executive Officer of the platform, integrating primary care clinics, medical centers, and multispecialty hospitals to widen community access, improve asset utilization, and support sustainable growth. The platform will focus on affordable healthcare and industrial health services across the UAE. 

The initiative is part of Burjeel 2.0, the Group’s transformation and operational alignment program, creating focused healthcare businesses with clearer accountability for clinical performance, patient experience, and financial outcomes. LLH, Lifecare, and Medeor will keep their unique identities while benefiting from shared leadership and operations within Burjeel’s broader ecosystem. 

A Broad Affordable Healthcare Footprint 

In the UAE, the platform brings together six hospitals, comprising Medeor in Abu Dhabi and Dubai, LLH in Abu Dhabi and Musaffah, and Lifecare in Musaffah and Baniyas, together with 24 medical centers and clinics, and more than 500 beds. The platform is supported by more than 2,400 physicians, nurses, and allied health professionals, with over 2.3 million outpatient visits and more than 61,000 admissions recorded in 2025. Together, these assets contributed 22.5% of Group revenue in FY2025 and 22.7% in H1 2026. 

All hospitals within the platform are JCI-accredited, reinforcing its commitment to internationally recognized standards of clinical quality and patient safety. The facilities provide primary, secondary, and multispecialty care, including complex surgeries, under unified clinical governance and quality standards. 

Expanding Access in Dubai 

Burjeel Holdings is planning a new 75-bed LLH Hospital in Jebel Ali, Dubai, to serve the area’s industrial workforce and surrounding communities. The facility will provide emergency, occupational, primary, and multispecialty care, supported by referral pathways to Burjeel’s advanced-care network. The project supports Burjeel’s strategy of expanding healthcare in high-growth, underserved communities while deploying capital efficiently. 

In addition to the new hospital, the platform plans to add more than 10 new clinics across the Emirates by expanding access for communities and major employment hubs. 

Established Platform with Scale & Strong Economics 

The businesses represent an established and significant revenue base, contributing more than a fifth of Group revenue, while continuing to expand their patient reach. 

The operating model is tailored to the segments it serves, with more affordable price points supported by a leaner cost base, including more efficient workforce deployment. As a result, the platform is able to maintain profitability comparable to the Group’s wider healthcare portfolio, while applying the same clinical quality and governance standards across the Group. 

Each brand will retain a defined role within the platform. LLH will continue to provide accessible community healthcare for middle- and lower-income populations. Lifecare serves industrial workforces and nearby communities, while Medeor serves middle-income expatriates and families in Abu Dhabi and Dubai. This positioning enables Burjeel to serve diverse patient and insurance segments while strengthening its role as a healthcare partner for employers, insurers, and communities. 

Integrated Care & Operational Alignment 

The platform will have unified leadership and oversight of patient growth, clinical outcomes, and financial performance. The structure supports procurement, workforce planning, and service development. 

Primary care and medical centers will serve as entry points into Burjeel’s wider healthcare network, supported by the platform’s multispecialty hospitals. Patients requiring more complex treatment can be seamlessly referred to the Group’s tertiary and quaternary facilities, including Burjeel Medical City, with follow-up care provided locally when appropriate. 

This connected model will improve continuity of care while extending access to Burjeel’s capabilities in oncology, cardiology, orthopedics, neurosciences, women’s health, transplantation, and other advanced specialties. 

Dr. Shamsheer Vayalil, Chairman and CEO of Burjeel Holdings, said: “The proven strength of these hospitals underlines the importance of affordable healthcare and its essential role in how we serve communities across the UAE. LLH, Lifecare, and Medeor have built strong relationships with the communities, families, and workforces they serve. Bringing them together under a unified vertical and leadership structure gives us a clearer framework to develop this business and use our resources more effectively. Our focus is on making quality healthcare close to people’s homes and workplaces.” 

Dr. Narendra, currently Regional Director of Operations for Medeor, LLH, and Lifecare Hospitals in Abu Dhabi, brings extensive experience in leading the Group’s healthcare brands and operations across the region. As CEO, he will oversee strategy, operations, clinical performance, and development, focusing on financial performance, capacity utilization, workforce planning, and expanding services for families, communities, and industrial workforces.

Recognition highlights the Institute’s comprehensive breast cancer program, accelerated diagnostic pathway, advanced treatment capabilities, research, and patient-centered care. 

Abu Dhabi, United Arab Emirates – 21 September 2026: Burjeel Cancer Institute at Burjeel Medical City (BMC) has been designated an Oncology Centre of Excellence for Breast Cancer by the Department of Health – Abu Dhabi (DoH), in recognition of its advanced capabilities in delivering world-class breast cancer care and driving excellence in patient outcomes. 

Burjeel Cancer Institute has been designated as a CoE for Oncology, Breast Cancer, for its advanced and specialized breast oncology capabilities. This is anchored by its One-Step Breast Clinic, which enables consultation, imaging, biopsy, pathology review, and treatment planning within 24 hours, significantly accelerating diagnosis and reducing treatment delays. 

The Institute is distinguished by its pioneering role in breast cancer research and in providing patients with access to the most advanced treatments available worldwide, offering Contrast-Enhanced Mammography (CEM), the GCC region’s only NOVALIS-accredited radiation oncology program, advanced oncoplastic and minimally invasive surgical techniques, and a UAE-wide mobile mammography program to deliver screening and education. 

Breast cancer remains one of the most common cancers among women in the UAE. In Abu Dhabi, early screening rates increased by 85% over the past year, reflecting the Emirate’s commitment to prevention, early detection and empowering community members to take proactive steps to protect their health. 

Centres of Excellence build on these prevention efforts by ensuring patients who require specialized treatment can access coordinated care, timely diagnosis, and advanced therapies through centers that meet the highest clinical standards, ultimately improving health outcomes and supporting patients in leading healthier, longer lives. 

Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: “Abu Dhabi continues to strengthen a leading healthcare ecosystem built on continuously advancing the quality of specialized care, fostering innovation and embedding a culture of excellence across the healthcare sector. The designation of Oncology Centres of Excellence for Breast Cancer marks another important milestone in this journey, recognizing providers that meet the highest standards of specialized care while encouraging continuous improvement across the healthcare ecosystem. By expanding access to trusted, high-quality specialized services, we are empowering our communities to receive the care they need, improving health outcomes, enhancing quality of life, and further reinforcing Abu Dhabi’s position as a global destination for healthcare.” 

Along with Burjeel Cancer Institute, Cleveland Clinic Abu Dhabi and SEHA Tawam Hospital have also been designated as Oncology Centres of Excellence for Breast Cancer by DoH. 

The three facilities have been designated as Oncology CoEs for Breast Cancer in recognition of their advanced capabilities in delivering world-class breast cancer care and driving excellence in patient outcomes. They provide end-to-end support across timely diagnosis, intervention, access to the latest treatment options, rehabilitation, and survivorship, while bringing together highly specialized, internationally trained teams across key disciplines to deliver coordinated, patient-centered treatment aligned with international standards and best practice. 

Professor Humaid Bin Harmal Al Shamsi, Chief Executive Officer of Burjeel Cancer Institute, said: “This designation represents an important milestone for Burjeel Cancer Institute and reflects our ongoing commitment to delivering specialized breast cancer care that meets the highest international standards. We have worked to build a comprehensive care model that places patients at the center of every decision, enabling faster access to accurate diagnosis, the latest treatment options and advanced technologies, while fostering close collaboration across medical specialties to achieve the best possible outcomes. We are proud to receive this recognition from the Department of Health – Abu Dhabi, which reinforces our commitment to continuing to invest in innovation, scientific research and the advancement of specialized care. This achievement also reflects our support for Abu Dhabi’s vision of becoming a leading global destination for advanced healthcare. Above all, it strengthens our ability to provide a seamless treatment journey that gives patients confidence and hope while helping to improve their quality of life.” 

CoEs are healthcare facilities designated by DoH to provide specialized programs in particular medical areas, in line with best practices and the highest quality standards. The facilities stand out with their world-class infrastructure, highly skilled and internationally accredited workforce, multidisciplinary resources, cutting-edge technologies and latest healthcare innovations, and clinical and scientific research while delivering best-in-class healthcare to patients in the emirate and beyond. 

CoEs must meet the minimum standard requirements issued by DoH, which outline the criteria and prerequisites for licensed healthcare facilities seeking the designation. DoH outlined six key indicators it considers when evaluating whether a healthcare facility can be recognized as a Centre of Excellence. The indicators cover clinical outcomes, patient experience, patient safety and quality of medical services, employee competency levels, and the facility's medical education, research strategies, and residency programs. DoH also assesses the accreditations to determine the healthcare facility’s eligibility to become a CoE.